drugset
drugset / Trial / NCT04504942

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

NCT04504942 ↗

Phase 2 Completed 16 enrolled CytoDyn, Inc. Amarex Clinical Research · collab
NaSingle-groupOpen-labelTreatment

Summary

A single arm phase II study with 30 patients of leronlimab (PRO 140) in patients with CCR5+ locally advanced or metastatic solid tumors.

Timeline

Start
2020-05-01
Primary completion
2021-11-07
Completion
2025-01-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Leronlimab Monoclonal antibody 525 mg Subcutaneous

Indications

cancer